The effect of food on the pharmacokinetics of WXFL10203614, a potential selective JAK1 inhibitor, in healthy Chinese subjects

被引:0
作者
Huang, Kai [1 ]
Shi, Yunfei [1 ]
Chu, Nannan [1 ]
Que, Linling [1 ]
Ding, Ying [1 ]
Qian, Zhenzhong [1 ]
Qin, Wei [1 ]
Gu, Xianghong [1 ]
Wang, Jiakun [1 ]
Zhang, Zhiwei [2 ]
Xu, Jianguo [2 ]
He, Qing [1 ]
机构
[1] Nanjing Med Univ, Drug Clin Trial Inst, Affiliated Wuxi Peoples Hosp, Wuxi, Peoples R China
[2] Wuxi Fuxin Pharmaceut Res & Dev Co Ltd, Wuxi, Peoples R China
关键词
WXFL10203614; pharmacokinetics; JAK1; inhibitor; rheumatoid arthritis; absorption; PHARMACODYNAMICS; SAFETY; BARICITINIB; PLACEBO;
D O I
10.3389/fphar.2022.1066895
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: This study was performed to investigate the effect of food on the pharmacokinetics (PK) of WXFL10203614 in healthy Chinese subjects. Methods: This was a randomized, open-label, single-dose, two-treatment (fed vs fasted), two-period, two-sequence, crossover study. 14 eligible subjects were averagely randomized into 2 sequences and then received 10 mg WXFL10203614 under fasted or fed condition. In each period, the blood samples were collected from 0 h (pre-dose) and serially up to 72 h post-dose, and plasma concentrations were detected using the high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method. The effect of food on the PK profile and safety of WXFL10203614 were assessed. Results: 70 subjects were screened, and 14 subjects (10 male and 4 female) were enrolled and completed the study. Under the fasted condition, WXFL10203614 was absorbed rapidly with a T-max of 0.98 h. The absorption rate was slower, T-max delayed by 2.98 h, and the C-max decreased by 16.3% when WXFL10203614 administered after the high-fat and high-calorie diet, other PK parameters were not affected. The 90% confidence intervals (CIs) for the ratio (fed/fasted) of geometric means of the C-max, AUC(0-t) and AUC(0-& INFIN;) were 0.73-1.01, 0.90-1.03 and 0.90-1.03, indicating that the high-fat and high-calorie diet might impact the absorption process of WXFL10203614. Although the C-max was slightly decreased, there was no significant difference in the C-max under fasted and fed conditions. Thus, it was not considered clinically significant owing to the small magnitude of changes in C-max. All Treatment-emergent adverse events (TEAEs) were mild and resolved spontaneously without treatment. Conclusion: Food had no clinically relevant effects on drug system exposure of WXFL10203614. It was well tolerated under fasted and fed conditions in healthy Chinese subjects, so WXFL10203614 could be administered orally with or without food.
引用
收藏
页数:8
相关论文
共 23 条
[1]   The Relative Bioavailability and Effects of Food and Acid-Reducing Agents on Filgotinib Tablets in Healthy Subjects [J].
Anderson, Kacey ;
Zheng, Hao ;
Kotecha, Mona ;
Cuvin, Jennifer ;
Scott, Bob ;
Sharma, Shringi ;
Qin, Ann Ran-Ran ;
Namour, Florence ;
Xin, Yan .
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2019, 8 (05) :585-594
[2]  
[Anonymous], 2012, Ema, DOI DOI 10.1093/DEAFED/ENS058
[3]   Clinical significance of Janus Kinase inhibitor selectivity [J].
Choy, Ernest H. .
RHEUMATOLOGY, 2019, 58 (06) :953-962
[4]  
Crispino N, 2021, CLIN EXP RHEUMATOL, V39, P668, DOI 10.55563/clinexprheumatol/e7ayu8
[5]   JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis [J].
Fragoulis, George E. ;
McInnes, Iain B. ;
Siebert, Stefan .
RHEUMATOLOGY, 2019, 58 :43-54
[6]   Tofacitinib inhibits granulocyte-macrophage colony-stimulating factor-induced NLRP3 inflammasome activation in human neutrophils [J].
Furuya, Makiko Yashiro ;
Asano, Tomoyuki ;
Sumichika, Yuya ;
Sato, Shuzo ;
Kobayashi, Hiroko ;
Watanabe, Hiroshi ;
Suzuki, Eiji ;
Kozuru, Hideko ;
Yatsuhashi, Hiroshi ;
Koga, Tomohiro ;
Ohira, Hiromasa ;
Sekine, Hideharu ;
Kawakami, Atsushi ;
Migita, Kiyoshi .
ARTHRITIS RESEARCH & THERAPY, 2018, 20
[7]   Safety, tolerability and pharmacokinetics of WXFL10203614 in healthy Chinese subjects: A randomized, double-blind, placebo-controlled phase I study [J].
Huang, Kai ;
Ding, Ying ;
Que, Linling ;
Chu, Nannan ;
Shi, Yunfei ;
Qian, Zhenzhong ;
Qin, Wei ;
Chen, Yuanxin ;
Gu, Xianghong ;
Wang, Jiakun ;
Zhang, Zhiwei ;
Xu, Jianguo ;
He, Qing .
FRONTIERS IN PHARMACOLOGY, 2022, 13
[8]   Extended-Release Once-Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate-Release Tofacitinib and Impact of Food [J].
Lamba, Manisha ;
Wang, Rong ;
Fletcher, Tracey ;
Alvey, Christine ;
Kushner, Joseph ;
Stock, Thomas C. .
JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 56 (11) :1362-1371
[9]   Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors - Similarities and differences [J].
Lennernas, H ;
Fager, G .
CLINICAL PHARMACOKINETICS, 1997, 32 (05) :403-425
[10]   Randomized, double-blinded, placebo-controlled phase I study of the pharmacokinetics, pharmacodynamics, and safety of KL130008, a novel oral JAK inhibitor, in healthy subjects [J].
Li, Na ;
Du, Shuangqing ;
Wang, Ying ;
Zhu, Xiaohong ;
Shu, Shiqing ;
Men, Yuchun ;
He, Miao ;
Fang, Fang ;
Wang, Yongsheng ;
Gong, Yimou ;
Chen, Jing ;
Gu, Liling ;
Cheng, Yezhe ;
He, Qiang ;
Lu, Huifang ;
Niu, Yuanyuan ;
Xu, Ying ;
Feng, Ping .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2022, 176